» Articles » PMID: 19141079

Effects of UCH-L1 on Alpha-synuclein Over-expression Mouse Model of Parkinson's Disease

Overview
Journal J Neurochem
Specialties Chemistry
Neurology
Date 2009 Jan 15
PMID 19141079
Citations 31
Authors
Affiliations
Soon will be listed here.
Abstract

The rare inherited form of Parkinson's disease (PD), PARK5, is caused by a missense mutation in ubiquitin carboxy-terminal hydrolase-L1 (UCH-L1) gene, resulting in Ile93Met substitution in its gene product (UCH-L1(Ile93Met)). PARK5 is inherited in an autosomal-dominant mode, but whether the Ile93Met mutation gives rise to a gain-of-toxic-function or loss-of-function of UCH-L1 protein remains controversial. Here, we investigated the selective vulnerabilities of dopaminergic (DA) neurons in UCH-L1-transgenic (Tg) and spontaneous UCH-L1-null gracile axonal dystrophy mice to an important PD-causing insult, abnormal accumulation of alpha-synuclein (alphaSyn). Immunohistochemistry of midbrain sections of a patient with sporadic PD showed alphaSyn- and UCH-L1-double-positive Lewy bodies in nigral DA neurons, suggesting physical and/or functional interaction between the two proteins in human PD brain. Recombinant adeno-associated viral vector-mediated over-expression of alphaSyn for 4 weeks significantly enhanced the loss of nigral DA cell bodies in UCH-L1(Ile93Met)-Tg mice, but had weak effects in age-matched UCH-L1(wild-type)-Tg mice and non-Tg littermates. In contrast, the extent of alphaSyn-induced DA cell loss in gracile axonal dystrophy mice was not significantly different from wild-type littermates at 13-weeks post-injection. Our results support the hypothesis that PARK5 is caused by a gain-of-toxic-function of UCH-L1(Ile93Met) mutant, and suggest that regulation of UCH-L1 in nigral DA cells could be a future target for treatment of PD.

Citing Articles

Ideal animal models according to multifaceted mechanisms and peculiarities in neurological disorders: present and challenges.

Lamichhane S, Seo J, Jeong J, Lee S, Lee S Arch Pharm Res. 2024; 48(1):62-88.

PMID: 39690343 DOI: 10.1007/s12272-024-01527-9.


-Synuclein ubiquitination - functions in proteostasis and development of Lewy bodies.

Ho H, Wing S Front Mol Neurosci. 2024; 17:1498459.

PMID: 39600913 PMC: 11588729. DOI: 10.3389/fnmol.2024.1498459.


Pathological mechanisms and treatment of sporadic Parkinson's disease: past, present, and future.

Mochizuki H J Neural Transm (Vienna). 2024; 131(6):597-607.

PMID: 38864935 PMC: 11192660. DOI: 10.1007/s00702-024-02788-w.


Ubiquitin Carboxyl-Terminal Hydrolase L1 and Its Role in Parkinson's Disease.

Buneeva O, Medvedev A Int J Mol Sci. 2024; 25(2).

PMID: 38279302 PMC: 10816476. DOI: 10.3390/ijms25021303.


Senolytic and senomorphic secondary metabolites as therapeutic agents in models of Parkinson's disease.

Miller S, Darji R, Walaieh S, Lewis J, Logan R Front Neurol. 2023; 14:1271941.

PMID: 37840914 PMC: 10568035. DOI: 10.3389/fneur.2023.1271941.